HLVX — HilleVax Income Statement
0.000.00%
Last trade - 00:00
HealthcareMid Cap
- $611.32m
- $333.08m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 0.633 | 1.29 | 53.4 | 65.1 | 133 |
Operating Profit | -0.633 | -1.29 | -53.4 | -65.1 | -133 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.673 | -2.1 | -102 | -160 | -124 |
Net Income After Taxes | -0.673 | -2.1 | -102 | -160 | -124 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.673 | -2.1 | -102 | -160 | -124 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.673 | -2.1 | -102 | -160 | -124 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.021 | -0.066 | -3.23 | -5.89 | -3.04 |
Dividends per Share |